By 2011, the El-Hibris’ connections had put Emergent in the driver’s seat. Despite its vaccine’s glaring and dangerous deficiencies, Emergent received $107 million in 2010 from Kadlec’s baby, BARDA,99 and up to $29 million from Fauci’s NIAID to develop NuThrax (its old anthrax vaccine with a new adjuvant) for large-scale manufacture in 2014.100
